About this trial
Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients.
Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear.
Pip5k1α is an important kinase involved in intracellular phosphatidylinositol signalling pathways that may be involved in smooth muscle contraction and diastole.
Therefore, further studies are necessary to elucidate the changes of Ezrin and Pip5k1α in patients with asthma to provide a basis for investigating alternative treatments for asthma.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Lung tissue samples;
The samples come from patients aged 18-70 years old, regardless of gender, who underwent lung tissue sampling for surgical indications during treatment;
Paraffin sections of lung tissue from patients diagnosed with bronchial asthma, including tracheal smooth muscle;
Paraffin sections of lung tissue from non-asthma patients, including tracheal smooth muscle.
Disqualifiers
Paraffin sections of lung tissue from patients who have been diagnosed with COPD;
Other situations where the researcher deems it inappropriate to participate in this study.
Trial population
Referring to previous validation studies of target proteins in the literature, the sample size required for this validation experiment is related to multiple factors: (1) Selection of genes: mRNA differentially expressed genes will have a 50% probability of differential protein expression. (2) Antibody selection: Commercially available antibodies will be used for immunohistochemical detection of formalin-fixed, paraffin-embedded tissues with a success rate of up to 75%. According to previous validation studies of the target protein, the required samples are 60 in each group, for a total of 120 samples.
Trial design
Case-control
Retrospective
Treatments tested in this trial
No intervention.
Other interventionObservational study with no intervention.
Treatment groups
Trial outcomes
Primary outcomes
Immunofluorescence results
IF
Immunohistochemistry results
IHC
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Lei-Miao Yin
Lead sponsor
Shanghai University of Traditional Chinese Medicine
Sponsor institution
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Collaborator
Shanghai 6th People's Hospital
Collaborator
Xiangya Hospital of Central South University
Collaborator
Baoshan Hospital, Shanghai University of Traditional Chinese Medicine
Collaborator
Shanghai Pulmonary Hospital, Shanghai, China
Collaborator